Brian R. Ott

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9

Cognitive Function in a Randomized Trial of Evolocumab

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · New England Journal of Medicine · 2017 · 466 citations · Full text

Neuropsychology, Cognition, Cognitive Rehabilitation +19

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial

Elaine R. Peskind, Steven G. Potkin, Nunzio Pomara et al. · American Journal of Geriatric Psychiatry · 2006 · 301 citations

Neurodegenerative Diseases, Geriatric Neurology, Alzheimer's Disease +11

Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease

Rebecca E. Ready, Brian R. Ott, Janet Grace · International Journal of Geriatric Psychiatry · 2004 · 243 citations

The Vascular Impairment of Cognition Classification Consensus Study

Olivia Anna Skrobot, John T. O’Brien, Sandra E. Black et al. · Alzheimer s & Dementia · 2016 · 224 citations · Full text